Filtered By:
Therapy: Chemotherapy
Vaccination: Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 902 results found since Jan 2013.
Research Progress in Immunotherapy of Gliomas
J Integr Neurosci. 2023 Aug 14;22(5):118. doi: 10.31083/j.jin2205118.ABSTRACTAlthough some progress has been made in tumor treatment, gliomas remain one of the tumors that can still seriously threaten human life and health. Due to the particularity of the immune microenvironment of the central nervous system and the strong invasiveness of tumors, the treatment of gliomas remains a major challenge. Currently, researchers have explored a large number of immunotherapy programs to improve the survival and prognosis of glioma patients, including tumor vaccines, immune checkpoint inhibitors, adoptive cell transfer therapy, viral...
Source: Journal of Integrative Neuroscience - September 21, 2023 Category: Neuroscience Authors: Zhi-Hong Duan Zi-Long Wei Source Type: research
Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1
CONCLUSION: In HLA-A2 positive patients with advanced NSCLC and secondary resistance to immunotherapy, OSE2101 increased survival with better safety compared to chemotherapy. Further evaluation in this population is warranted.PMID:37704166 | DOI:10.1016/j.annonc.2023.07.006
Source: Ann Oncol - September 13, 2023 Category: Cancer & Oncology Authors: B Besse E Felip R Garcia Campelo M Cobo C Mascaux A Madroszyk F Cappuzzo W Hilgers G Romano F Denis S Viteri D Debieuvre D Galetta E Baldini None M Razaq G Robinet M Maio A Delmonte B Roch P Masson W Schuette A Zer J Remon D Costantini B Vasseur R Dziadzi Source Type: research
Recurrent Glioblastoma: A Review of the Treatment Options
Cancers (Basel). 2023 Aug 26;15(17):4279. doi: 10.3390/cancers15174279.ABSTRACTGlioblastoma is a disease with a poor prognosis. Multiple efforts have been made to improve the long-term outcome, but the 5-year survival rate is still 5-10%. Recurrence of the disease is the usual way of progression. In this situation, there is no standard treatment. Different treatment options can be considered. Among them would be reoperation or reirradiation. There are different studies that have assessed the impact on survival and the selection of patients who may benefit most from these strategies. Chemotherapy treatments have also been c...
Source: Hand Surgery - September 9, 2023 Category: Surgery Authors: Maria Angeles Vaz-Salgado Mar ía Villamayor V íctor Albarrán V íctor Alía Pilar Sotoca Jes ús Chamorro Diana Rosero Ana M Barrill Mercedes Mart ín Eva Fernandez Jos é Antonio Gutierrez Luis Mariano Rojas-Medina Luis Ley Source Type: research
Graphene oxide nanoarchitectures in cancer therapy: Drug and gene delivery, phototherapy, immunotherapy, and vaccine development
Environ Res. 2023 Aug 31:117027. doi: 10.1016/j.envres.2023.117027. Online ahead of print.ABSTRACTThe latest advancements in oncology involves the creation of multifunctional nanostructures. The integration of nanoparticles into the realm of cancer therapy has brought about a transformative shift, revolutionizing the approach to addressing existing challenges and limitations in tumor elimination. This is particularly crucial in combating the emergence of resistance, which has significantly undermined the effectiveness of treatments like chemotherapy and radiotherapy. GO stands as a carbon-derived nanoparticle that is incre...
Source: Environmental Research - September 2, 2023 Category: Environmental Health Authors: Mohammad Saleh Sadeghi Faezeh Hosseini Sangrizeh Negar Jahani Mahdi Sadegh Abedin Soheila Chaleshgari Alireza Khodaei Ardakan Reza Baeelashaki Golnaz Ranjbarpazuki Parham Rahmanian Mohammad Arad Zandieh Noushin Nabavi Amir Reza Aref Shokooh Salimimoghadam Source Type: research
A Comprehensive Review on Current Treatments and Challenges Involved in the Treatment of Ovarian Cancer
In conclusion, tailored nanocarriers would optimize medication delivery into the intracellular compartment before optimizing intra-tumour distribution. Other novel treatment possibilities for ovarian cancer include tumour vaccines, gene therapy, targeting epigenetic alteration, and biologically targeted compounds. These characteristics might enhance the therapeutic efficacy.PMID:37642226 | DOI:10.2174/1568009623666230811093139
Source: Current Cancer Drug Targets - August 29, 2023 Category: Cancer & Oncology Authors: Saika Saman Nimisha Srivastava Mohd Yasir Iti Chauhan Source Type: research
Chemotherapy-induced nanovaccines implement immunogenicity equivalence for improving cancer chemoimmunotherapy
Biomaterials. 2023 Aug 21;301:122290. doi: 10.1016/j.biomaterials.2023.122290. Online ahead of print.ABSTRACTSeveral chemoimmunotherapies have been approved by the FDA for the treatment of various cancers. Chemotherapy has the potential to improve the efficacy of immunotherapy by inducing immunogenic cell death (ICD) of tumor cells, promoting the release of tumor associated antigens (TAAs), tumor specific antigens (TSAs) and damage associated molecular patterns (DAMPs), and disrupting immunosuppressive microenvironments by tumor debulking. Unfortunately, systemic administration of chemotherapeutics carries side effects of ...
Source: Biomaterials - August 29, 2023 Category: Materials Science Authors: Rui Li Yuhao Hao Kyle Roche Guiyuan Chen Wen Pan Andrew Z Wang Yuanzeng Min Source Type: research
Breast cancer vaccines; A comprehensive and updated review
Pathol Res Pract. 2023 Aug 4;249:154735. doi: 10.1016/j.prp.2023.154735. Online ahead of print.ABSTRACTAccording to the International Agency for Research on Cancer, breast cancer is more common than lung cancer globally. By 2040, mortality from breast cancer will rise by 50% and 40%, respectively. Despite advances in chemotherapy, endocrine therapy, and HER2-targeted therapy, breast cancer metastases and recurrences remain challenging to treat. Cancer vaccines are an effective treatment option because they stimulate a long-lasting immune response that will eliminate tumor cells. In studies on the breast cancer vaccine, no ...
Source: Pathology, Research and Practice - August 23, 2023 Category: Pathology Authors: Sulieman Ibraheem Shelash Al-Hawary Ebraheem Abdu Musad Saleh Nodirjon Akhmetovich Mamajanov Nataliya S Gilmanova Hashem O Alsaab Adel Alghamdi Shakeel Ahmed Ansari Ahmed Hussien Radie Alawady Ali Hashiem Alsaalamy Ahmed Jaber Ibrahim Source Type: research
Albumin pre-opsonized membrane-active iPep nanomedicine potentiates chemo to immunotherapy of cancer
Biomaterials. 2023 Aug 8;301:122269. doi: 10.1016/j.biomaterials.2023.122269. Online ahead of print.ABSTRACTChemotherapy-conjugated immunotherapy in clinical oncology conceptually resembles the combined effects of cytoreduction and immunostimulation in membrane targeted cell killings mediated by pore-forming proteins or host defense peptides. Of the similar concept, targeting cancer cell membrane using membrane active peptides is a hopeful therapeutic modality but had long been hindered from in vivo application. Here we report an enabling strategy of pre-opsonizing a membrane penetrating Ir-complexed octa-arginine peptide ...
Source: Biomaterials - August 13, 2023 Category: Materials Science Authors: Shuangshuang Ji Liu Huang Shiwei Chang Xingwei Sun Hanjie Liu Ang Li Yong Jin Hao Fei Source Type: research
Liquid nitrogen frozen cells for chemotherapy drug delivery and vaccination of melanoma
CONCLUSION: In this work, we obtain the LNF cells with a simple procedure. The LNF cells not only provides a tumor cells-based multi-modal system for cancer therapy but inspires new insights into future development of individualized CVs strategies. This study processes live B16F10 cells by liquid nitrogen frozen to obtain LNF cells, which preserve cell integrity and homologous targeting ability. The LNF cells can load and deliver drug and can serve as tumor vaccine. Results demonstrated the LNF cells have effective prophylactic ability, and ideal anti-tumor ability with the loaded drug and adjuvant.PMID:37522925 | DOI:10.1...
Source: Cancer Control - July 31, 2023 Category: Cancer & Oncology Authors: Minliang Wu Yuai Xiao Jianguo Huang Yuchong Wang Yifan Zhang Jianguo Xu Haiying Dai Chuan Lv Yihui Hu Bingdi Chen Qingge Fu Wenjun Le Chunyu Xue Source Type: research
